Article Text

PDF
P298 Tiotropium/olodaterol therapy provides symptomatic benefits irrespective of prior maintenance treatment: post hoc analyses of the otemto® studies

Abstract

R Abrahams reports grants and personal fees from Boehringer Ingelheim during the conduct of the study and, outside of this work, grants and personal fees from GlaxoSmithKline and grants from AstraZeneca and Pearl Therapeutics.

GT Ferguson, during the conduct of the study, reports grants, personal fees and non-financial support from Boehringer Ingelheim and, outside the submitted work, grants, personal fees and non-financial support from Boehringer Ingelheim, personal fees from GlaxoSmithKline, grants and personal fees from Novartis, AstraZeneca, Pearl Therapeutics and Sunovion, and grants from Forest.

L Bjermer reports no conflicts of interest.

L Grönke and F Voß are employees of Boehringer Ingelheim Pharma GmbH & Co. KG.

D Singh reports other financial activities from Boehringer Ingelheim during the conduct of the study and, outside of the submitted work, grants and personal fees from Almirall, AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Glenmark, Johnson & Johnson, Merck, NAPP, Novartis, Pfizer, Takeda, Teva, Theravance and Verona, and personal fees from Genentech and SkyePharma.

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.